As seasonal influenza continues to impact healthcare systems worldwide, rapid and accurate respiratory virus detection remains a critical component of disease management. Healthcare providers, clinics, laboratories, and public health organizations are increasingly seeking reliable point-of-care diagnostic solutions that can support timely decision-making.
The Influenza A/B Antigen Detection Kit (Colloidal Gold Method) from BABIO, a leading Chinese manufacturer of in-vitro diagnostic products, is designed to provide rapid qualitative detection of Influenza A and Influenza B antigens through a convenient lateral flow immunochromatographic assay.
Using advanced colloidal gold technology, the test enables efficient identification of influenza virus antigens from clinical specimens. Distinct test lines allow differentiation between Influenza A and Influenza B, while an integrated control line ensures test validity and quality assurance throughout the testing process.
With increasing awareness of respiratory infectious diseases, rapid flu diagnostic tests have become essential tools for healthcare professionals worldwide. Early detection can help support clinical assessment, patient management, and infection control strategies, particularly during seasonal influenza outbreaks.
As a trusted manufacturer in China, BABIO continues to supply high-quality diagnostic products to global healthcare markets, serving distributors, hospitals, laboratories, and public health institutions.
For detailed product specifications, technical support, and partnership opportunities, please visit the official BABIO website:
BABIO remains committed to delivering innovative diagnostic solutions that contribute to global healthcare and infectious disease detection.
#InfluenzaTest
#RapidFluTest
#InfluenzaA
#InfluenzaB
#RespiratoryDiagnostics
#PointOfCareTesting
#RapidAntigenTest
#IVD
#DiagnosticKit
#HealthcareDiagnostics
#MedicalLaboratory
#BABIO
#ColloidalGoldTest
#InfectiousDiseaseTesting
#FluSeason
Please give us a message